Dr. Rathkopf on AR-V7 Biomarker in Prostate Cancer

Dana E. Rathkopf, MD
Published: Thursday, Jan 26, 2017



Dana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center, discusses the emergence of the androgen receptor splice variant-7 (AR-V7) biomarker in the treatment of patients with prostate cancer.

AR-V7 has been previously studied in circulating tumor cells in men with castration-resistant prostate cancer to identify primary resistance to enzalutamide (Xtandi) and abiraterone acetate (Zytiga) therapy.

AR-V7 is currently being looked at as a biomarker to find an appropriate patient population, wherein physicians then may be able to use combinations of other drugs to overcome resistance to targeted therapy.

According to Rathkopf, biomarkers like this are the key to understanding and mitigating resistance in prostate cancer.
 
SELECTED
LANGUAGE


Dana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center, discusses the emergence of the androgen receptor splice variant-7 (AR-V7) biomarker in the treatment of patients with prostate cancer.

AR-V7 has been previously studied in circulating tumor cells in men with castration-resistant prostate cancer to identify primary resistance to enzalutamide (Xtandi) and abiraterone acetate (Zytiga) therapy.

AR-V7 is currently being looked at as a biomarker to find an appropriate patient population, wherein physicians then may be able to use combinations of other drugs to overcome resistance to targeted therapy.

According to Rathkopf, biomarkers like this are the key to understanding and mitigating resistance in prostate cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x